# REVErsing Airway Remodelling With Tezepelumab

> **NCT05651841** · PHASE3 · RECRUITING · sponsor: **University Hospital, Montpellier** · enrollment: 90 (estimated)

## Conditions studied

- Airway Remodelling, Asthmatic

## Interventions

- **DRUG:** Tezepelumab
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT05651841
- **Lead sponsor:** University Hospital, Montpellier
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-27
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05651841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05651841, "REVErsing Airway Remodelling With Tezepelumab". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05651841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*